Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

  • Garcia Valero, Juan
  • Matas-Céspedes, Alba
  • Arenas, Fabián
  • Rodriguez, Vanina
  • Carreras, Joaquim
  • Serrat, Neus
  • Guerrero-Hernández, Martina
  • Yahiaoui, Anella
  • Balagué, Olga
  • Martin, Silvia
  • Capdevila, Cristina
  • Hernández, Lluis
  • Magnano, Laura
  • Rivas-Delgado, Alfredo
  • Tannheimer, Stacey
  • Cid, Maria C.
  • Campo, Elias
  • López Guillermo, Armando
  • Colomer Pujol, Dolors
  • Pérez-Galán, Patricia
Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival with macrophages playing a controversial role. In the present study, using FL primary samples and HK follicular dendritic cells (FDC) to mimic the germinal center, together with mouse models, we have analyzed the three-way crosstalk of FL-FDC-macrophages and derived therapeutic opportunities. Ex vivo primary FL-FDC co-cultures (n = 19) and in vivo mouse co-xenografts demonstrated that FL-FDC crosstalk favors tumor growth and, via the secretion of CCL2 and CSF-1, promotes monocyte recruitment, differentiation, and polarization towards an M2-like protumoral phenotype. Moreover, FL-M2 co-cultures displayed enhanced angiogenesis, dissemination, and immunosuppression. Analysis of the CSF-1/CSF-1R pathway uncovered that CSF-1 was significantly higher in serum from grade 3A FL patients, and that high CSF-1R expression in FL biopsies correlated with grade 3A, reduced overall survival and risk of transformation. Furthermore, CSF-1R inhibition with pexidartinib (PLX3397) preferentially affected M2-macrophage viability and polarization program disrupting FL-M2 positive crosstalk. In vivo CSF1-R inhibition caused M2 reduction and repolarization towards M1 macrophages and antitumor effect cooperating with anti-CD20 rituximab. In summary, these results support the role of macrophages in FL pathogenesis and indicate that CSF-1R may be a relevant prognostic factor and a novel therapeutic target cooperating with anti-CD20 immunotherapy., Grants that contributed to this work included: Gilead Sciences Research Funded Agreement, Spanish Ministry of Economy and Competitiveness & European Regional Development Fund (ERDF) “Una manera de hacer Europa” for SAF2014/57708R and SAF2017/ 88275R to PP-G and MCC, RTI2018-094584-B-I00 to DC, CIBERONC (CB16/12/00334 and CB16/12/00225), and finally Generalitat de Catalunya support for AGAUR 2017SGR1009 to DC
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma

  • Bachiller, Mireia
  • Ferruz Capapey, Noelia, 1988-
  • Guedan, Sonia
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given the co-expression of CD19 and BCMA in NHL, we hypothesized that dual targeting could enhance long-term efficacy. We optimized different dual-targeting approaches, including co-transduction of two lentiviral vectors, bicistronic, tandem, and loop and pool strategies, based on our academic anti-CD19 (ARI0001) and anti-BCMA (ARI0002h) CAR-T cells. Comparison with anti-CD19/CD20 or anti-CD19/CD22 dual targeting was also performed. We demonstrate that anti-CD19/BCMA CAR-T cells can be effectively generated through the co-transduction of two lentiviral vectors after optimization to minimize competition for cellular resources. Co-transduced T cells, called ARI0003, effectively targeted NHL tumor cells with high avidity, outperforming anti-CD19 CAR-T cells and other dual-targeting approaches both in vitro and in vivo, particularly in low CD19 antigen density models. ARI0003 maintained effectiveness post-CD19 CAR-T treatment in xenograft models and in spheroids from relapsed CART-treated patients. ARI0003 CAR-T cells were effectively manufactured under Good Manufacturing Practice conditions, with a reduced risk of genotoxicity compared to other dual-targeting approaches. A first-in-human phase 1 clinical trial (CARTD-BG-01; this study was registered at ClinicalTrials.gov [NCT06097455]) has been initiated to evaluate the safety and efficacy of ARI0003 in NHL., This study was supported by research funding from “'la Caixa” Foundation to M.J. (LCF/PR/SP23/52950004); the Spanish Ministry of Science and Innovation under a Ramon y Cajal grant RYC2018-024442-I to S.G. and PID2020-119692RB-C22 to C.F.; the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 116026 to S.G. (this joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations), the Spanish Association Against Cancer (INVES222988RODR to A.R.-G.), and the AGAUR_INVESTIGO22 100028TC1 grant, within the framework of the Recovery, Transformation, and Resilience Plan, funded by the European Union’s NextGenerationEU Recovery Mechanism. C.D.-L. was supported by a personal "Formación de personal investigador" fellowship from the Ministry of Economy and competitiveness (PRE2018-083797) associated with the project SAF2017-88275-R to P.P.-G. We also thank the Generalitat de Catalunya for support (AGAUR 2021-SGR-01294) to P.P.-G. M.O.-M. was granted a "Formacion para investigadores en el ámbito de la Investigacin sanitaria" predoctoral training grant (IFI18/00035). B.M.-A. was supported by the Miguel Servet program (grant no. CP21/00111) of the Institute of Health Carlos III. We also acknowledge the support of the CERCA Programme/Generalitat de Catalunya. This work was developed at the Centro Esther Koplowitz, Barcelona, Spain. We thank the Flow Cytometry and Cell Sorting core facility of Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS) for their technical help. We also thank the animal facility of the University of Barcelona.
Repisalud
Publicación Artículo científico (JournalArticle)

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.

  • Bachiller, Mireia
  • Barceló-Genestar, Nina
  • Rodriguez-Garcia, Alba
  • Alserawan, Leticia
  • Dobaño-López, Cèlia
  • Giménez-Alejandre, Marta
  • Castellsagué, Joan
  • Colell, Salut
  • Otero-Mateo, Marc
  • Antoñana-Vildosola, Asier
  • Español-Rego, Marta
  • Ferruz, Noelia
  • Pascal, Mariona
  • Martín-Antonio, Beatriz
  • Anguela, Xavier M
  • Fillat, Cristina
  • Olesti, Eulàlia
  • Calvo, Gonzalo
  • Juan, Manel
  • Delgado, Julio
  • Pérez-Galán, Patricia
  • Urbano-Ispizua, Álvaro
  • Guedan, Sonia
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given the co-expression of CD19 and BCMA in NHL, we hypothesized that dual targeting could enhance long-term efficacy. We optimized different dual-targeting approaches, including co-transduction of two lentiviral vectors, bicistronic, tandem, and loop and pool strategies, based on our academic anti-CD19 (ARI0001) and anti-BCMA (ARI0002h) CAR-T cells. Comparison with anti-CD19/CD20 or anti-CD19/CD22 dual targeting was also performed. We demonstrate that anti-CD19/BCMA CAR-T cells can be effectively generated through the co-transduction of two lentiviral vectors after optimization to minimize competition for cellular resources. Co-transduced T cells, called ARI0003, effectively targeted NHL tumor cells with high avidity, outperforming anti-CD19 CAR-T cells and other dual-targeting approaches both in vitro and in vivo, particularly in low CD19 antigen density models. ARI0003 maintained effectiveness post-CD19 CAR-T treatment in xenograft models and in spheroids from relapsed CART-treated patients. ARI0003 CAR-T cells were effectively manufactured under Good Manufacturing Practice conditions, with a reduced risk of genotoxicity compared to other dual-targeting approaches. A first-in-human phase 1 clinical trial (CARTD-BG-01; this study was registered at ClinicalTrials.gov [NCT06097455]) has been initiated to evaluate the safety and efficacy of ARI0003 in NHL.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway

  • Beà, Aida
  • García Valero, Juan
  • Irazoki, Andrea
  • Lana, Carlos
  • López-Lluch, Guillermo
  • Portero-Otín, Manuel
  • Pérez-Galán, Patricia
  • Inserte, Javier
  • Ruiz-Meana, Marisol
  • Zorzano, Antonio
  • Llovera, Marta
  • Sanchis, Daniel
Cardiovascular diseases are the leading cause of death globally and more than four out of five cases are due to ischemic events. Cardiac fibroblasts (CF) contribute to normal heart development and function, and produce the post-ischemic scar. Here, we characterize the biochemical and functional aspects related to CF endurance to ischemia-like conditions. Expression data mining showed that cultured human CF (HCF) express more BCL2 than pulmonary and dermal fibroblasts. In addition, gene set enrichment analysis showed overrepresentation of genes involved in the response to hypoxia and oxidative stress, respiration and Janus kinase (JAK)/Signal transducer and Activator of Transcription (STAT) signaling pathways in HCF. BCL2 sustained survival and proliferation of cultured rat CF, which also had higher respiration capacity and reactive oxygen species (ROS) production than pulmonary and dermal fibroblasts. This was associated with higher expression of the electron transport chain (ETC) and antioxidant enzymes. CF had high phosphorylation of JAK2 and its effectors STAT3 and STAT5, and their inhibition reduced viability and respiration, impaired ROS control and reduced the expression of BCL2, ETC complexes and antioxidant enzymes. Together, our results identify molecular and biochemical mechanisms conferring survival advantage to experimental ischemia in CF and show their control by the JAK2/STAT signaling pathway. The presented data point to potential targets for the regulation of cardiac fibrosis and also open the possibility of a general mechanism by which somatic cells required to acutely respond to ischemia are constitutively adapted to survive it., This research was funded by Ministerio de Ciencia e Innovación (MICINN), Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to DS; Fundació La Marató TV3, grant number 20153810 to D.S; A.B. holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida; Generalitat de Catalunya, (AGAUR) grant number 2017SGR996 to DS; PP-G Laboratory support was obtained through research grants from MICINN (SAF2017/88275R) and CIBERONC (CB16/12/00334); JI and MR-M Laboratory support was obtained from Instituto de Salud Carlos III (ISCIII-FIS) grant PI19-01196; AZ Laboratory support was obtained through research grants from MICINN (PID2019-106209RB-I00), and the Generalitat de Catalunya, (AGAUR) grant number 2017SGR1015. AZ is a recipient of an ICREA ‘Academia’ Award (Generalitat de Catalunya). We gratefully acknowledge institutional funding from the MINECO through the Centres of Excellence Severo Ochoa Award, and from the CERCA Programme of the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma

  • Bachiller, Mireia
  • Ferruz Capapey, Noelia, 1988-
  • Guedan, Sonia
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given the co-expression of CD19 and BCMA in NHL, we hypothesized that dual targeting could enhance long-term efficacy. We optimized different dual-targeting approaches, including co-transduction of two lentiviral vectors, bicistronic, tandem, and loop and pool strategies, based on our academic anti-CD19 (ARI0001) and anti-BCMA (ARI0002h) CAR-T cells. Comparison with anti-CD19/CD20 or anti-CD19/CD22 dual targeting was also performed. We demonstrate that anti-CD19/BCMA CAR-T cells can be effectively generated through the co-transduction of two lentiviral vectors after optimization to minimize competition for cellular resources. Co-transduced T cells, called ARI0003, effectively targeted NHL tumor cells with high avidity, outperforming anti-CD19 CAR-T cells and other dual-targeting approaches both in vitro and in vivo, particularly in low CD19 antigen density models. ARI0003 maintained effectiveness post-CD19 CAR-T treatment in xenograft models and in spheroids from relapsed CART-treated patients. ARI0003 CAR-T cells were effectively manufactured under Good Manufacturing Practice conditions, with a reduced risk of genotoxicity compared to other dual-targeting approaches. A first-in-human phase 1 clinical trial (CARTD-BG-01; this study was registered at ClinicalTrials.gov [NCT06097455]) has been initiated to evaluate the safety and efficacy of ARI0003 in NHL., This study was supported by research funding from “'la Caixa” Foundation to M.J. (LCF/PR/SP23/52950004); the Spanish Ministry of Science and Innovation under a Ramon y Cajal grant RYC2018-024442-I to S.G. and PID2020-119692RB-C22 to C.F.; the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 116026 to S.G. (this joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations), the Spanish Association Against Cancer (INVES222988RODR to A.R.-G.), and the AGAUR_INVESTIGO22 100028TC1 grant, within the framework of the Recovery, Transformation, and Resilience Plan, funded by the European Union’s NextGenerationEU Recovery Mechanism. C.D.-L. was supported by a personal "Formación de personal investigador" fellowship from the Ministry of Economy and competitiveness (PRE2018-083797) associated with the project SAF2017-88275-R to P.P.-G. We also thank the Generalitat de Catalunya for support (AGAUR 2021-SGR-01294) to P.P.-G. M.O.-M. was granted a "Formacion para investigadores en el ámbito de la Investigacin sanitaria" predoctoral training grant (IFI18/00035). B.M.-A. was supported by the Miguel Servet program (grant no. CP21/00111) of the Institute of Health Carlos III. We also acknowledge the support of the CERCA Programme/Generalitat de Catalunya. This work was developed at the Centro Esther Koplowitz, Barcelona, Spain. We thank the Flow Cytometry and Cell Sorting core facility of Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS) for their technical help. We also thank the animal facility of the University of Barcelona.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

  • Garcia Valero, Juan
  • Matas-Céspedes, Alba
  • Arenas, Fabián
  • Rodriguez, Vanina
  • Carreras, Joaquim
  • Serrat, Neus
  • Guerrero-Hernández, Martina
  • Yahiaoui, Anella
  • Balagué, Olga
  • Martin, Silvia
  • Capdevila, Cristina
  • Hernández, Lluis
  • Magnano, Laura
  • Rivas-Delgado, Alfredo
  • Tannheimer, Stacey
  • Cid, Maria C.
  • Campo, Elias
  • López Guillermo, Armando
  • Colomer Pujol, Dolors
  • Pérez-Galán, Patricia
Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival with macrophages playing a controversial role. In the present study, using FL primary samples and HK follicular dendritic cells (FDC) to mimic the germinal center, together with mouse models, we have analyzed the three-way crosstalk of FL-FDC-macrophages and derived therapeutic opportunities. Ex vivo primary FL-FDC co-cultures (n = 19) and in vivo mouse co-xenografts demonstrated that FL-FDC crosstalk favors tumor growth and, via the secretion of CCL2 and CSF-1, promotes monocyte recruitment, differentiation, and polarization towards an M2-like protumoral phenotype. Moreover, FL-M2 co-cultures displayed enhanced angiogenesis, dissemination, and immunosuppression. Analysis of the CSF-1/CSF-1R pathway uncovered that CSF-1 was significantly higher in serum from grade 3A FL patients, and that high CSF-1R expression in FL biopsies correlated with grade 3A, reduced overall survival and risk of transformation. Furthermore, CSF-1R inhibition with pexidartinib (PLX3397) preferentially affected M2-macrophage viability and polarization program disrupting FL-M2 positive crosstalk. In vivo CSF1-R inhibition caused M2 reduction and repolarization towards M1 macrophages and antitumor effect cooperating with anti-CD20 rituximab. In summary, these results support the role of macrophages in FL pathogenesis and indicate that CSF-1R may be a relevant prognostic factor and a novel therapeutic target cooperating with anti-CD20 immunotherapy., Grants that contributed to this work included: Gilead Sciences Research Funded Agreement, Spanish Ministry of Economy and Competitiveness & European Regional Development Fund (ERDF) “Una manera de hacer Europa” for SAF2014/57708R and SAF2017/ 88275R to PP-G and MCC, RTI2018-094584-B-I00 to DC, CIBERONC (CB16/12/00334 and CB16/12/00225), and finally Generalitat de Catalunya support for AGAUR 2017SGR1009 to DC
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status

  • Lyons, Paul A.
  • Peters, James E.
  • Alberici, Federico
  • Liley, James
  • Coulson, Richard M. R.
  • Astle, William
  • Baldini, Chiara
  • Bonatti, Francesco
  • Cid, María Cinta|||0000-0002-4730-0938
  • Elding, Heather
  • Emmi, Giacomo|||0000-0001-9575-8321
  • Epplen, Jörg
  • Guillevin, Loïc
  • Jayne, David R. W.
  • Jiang, Tao
  • Gunnarsson, Iva
  • Lamprecht, Peter
  • Leslie, Stephen
  • Little, Mark A.
  • Martorana, Davide
  • Moosig, Frank
  • Neumann, Thomas
  • Ohlsson, Sophie|||0000-0002-5253-1650
  • Quickert, Stefan
  • Ramirez, Giuseppe A.
  • Rewerska, Barbara
  • Schett, George
  • Sinico, Renato A.
  • Szczeklik, Wojciech|||0000-0002-1349-1123
  • Tesar, Vladimir|||0000-0001-6982-0689
  • Vukcevic, Damjan
  • Akil, Mohammed
  • Barratt, Jonathan
  • Basu, Neil
  • Butterworth, Adam|||0000-0002-6915-9015
  • Bruce, Ian
  • Clarkson, Michael
  • Conlon, Niall
  • DasGupta, Bhaskar
  • Doulton, Timothy W. R.
  • Espígol Frigolé, Georgina|||0000-0002-8299-0209
  • Flossmann, Oliver
  • Gabrielli, Armando
  • Gasior, Jolanta
  • Gregorini, Gina
  • Guida, Giuseppe
  • Hernández Rodríguez, José|||0000-0002-2357-2015
  • Hruskova, Zdenka
  • Hudson, Amy
  • Knight, Ann
  • Lanyon, Peter
  • Luqmani, Raashid|||0000-0002-4446-5841
  • Magliano, Malgorzata
  • Manfredi, Angelo A.
  • Marguerie, Christopher
  • Maritati, Federica
  • Marvisi, Chiara
  • McHugh, Neil J.|||0000-0003-2765-658X
  • Molloy, Eaminn
  • Motyer, Allan
  • Mukhtyar, Chetan
  • Padyukov, Leonid|||0000-0003-2950-5670
  • Pesci, Alberto
  • Prieto-Gonzalez, Sergio
  • Ramentol-Sintas, Marc
  • Reis, Petra
  • Roccatello, Dario
  • Rovere-Querini, Patrizia
  • Salvarani, Carlo|||0000-0001-5426-5133
  • Santarsia, Francesca
  • Solans, Roser|||0000-0002-0058-1293
  • Soranzo, Nicole|||0000-0003-1095-3852
  • Taylor, Jo
  • Wessels, Julie
  • Zwerina, Jochen
  • Terrier, Benjamin|||0000-0001-6612-7336
  • Watts, Richard A.
  • Vaglio, Augusto
  • Holle, Julia U.
  • Wallace, Chris
  • Smith, Kenneth G. C.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% of patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we describe a genome-wide association study in 676 EGPA cases and 6809 controls, that identifies 4 EGPA-associated loci through conventional case-control analysis, and 4 additional associations through a conditional false discovery rate approach. Many variants are also associated with asthma and six are associated with eosinophil count in the general population. Through Mendelian randomisation, we show that a primary tendency to eosinophilia contributes to EGPA susceptibility. Stratification by ANCA reveals that EGPA comprises two genetically and clinically distinct syndromes. MPO+ ANCA EGPA is an eosinophilic autoimmune disease sharing certain clinical features and an HLA-DQ association with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a mucosal/barrier dysfunction origin. Four candidate genes are targets of therapies in development, supporting their exploration in EGPA.